101 related articles for article (PubMed ID: 20608756)
1. Population pharmacokinetics of gemcitabine and its metabolite in Japanese cancer patients: impact of genetic polymorphisms.
Sugiyama E; Kaniwa N; Kim SR; Hasegawa R; Saito Y; Ueno H; Okusaka T; Ikeda M; Morizane C; Kondo S; Yamamoto N; Tamura T; Furuse J; Ishii H; Yoshida T; Saijo N; Sawada J
Clin Pharmacokinet; 2010 Aug; 49(8):549-58. PubMed ID: 20608756
[TBL] [Abstract][Full Text] [Related]
2. Intracellular Cytidine Deaminase Regulates Gemcitabine Metabolism in Pancreatic Cancer Cell Lines.
Bjånes TK; Jordheim LP; Schjøtt J; Kamceva T; Cros-Perrial E; Langer A; Ruiz de Garibay G; Kotopoulis S; McCormack E; Riedel B
Drug Metab Dispos; 2020 Mar; 48(3):153-158. PubMed ID: 31871136
[TBL] [Abstract][Full Text] [Related]
3. A phase 1, open-label, dose escalation study of intravenous paricalcitol in combination with gemcitabine in patients with advanced malignancies.
Fountzilas C; Javle M; Tan W; Ma Y; Fetterly G; Iyer R; Johnson C
Cancer; 2018 Oct; 124(19):3890-3899. PubMed ID: 30299542
[TBL] [Abstract][Full Text] [Related]
4. Deciphering the role of Enterococcus faecium cytidine deaminase in gemcitabine resistance of gallbladder cancer.
Jiang L; Zhang L; Shu Y; Zhang Y; Gao L; Qiu S; Zhang W; Dai W; Chen S; Huang Y; Liu Y
J Biol Chem; 2024 Apr; 300(4):107171. PubMed ID: 38492776
[TBL] [Abstract][Full Text] [Related]
5. Tetrahydrouridine inhibits cell proliferation through cell cycle regulation regardless of cytidine deaminase expression levels.
Funamizu N; Lacy CR; Fujita K; Furukawa K; Misawa T; Yanaga K; Manome Y
PLoS One; 2012; 7(5):e37424. PubMed ID: 22616006
[TBL] [Abstract][Full Text] [Related]
6. Loss of cytidine deaminase expression as a potential attempt to counteract the process of carcinogenesis by reducing basal PARP-1 activity and increasing tau levels.
Amor-Guéret M
Biochim Biophys Acta Mol Basis Dis; 2024 Jun; 1870(5):167213. PubMed ID: 38714266
[TBL] [Abstract][Full Text] [Related]
7. A Cathepsin B-Sensitive Gemcitabine Prodrug for Enhanced Pancreatic Cancer Therapy.
Wang S; Cen D; Zhang C
J Pharm Sci; 2024 Mar; ():. PubMed ID: 38555998
[TBL] [Abstract][Full Text] [Related]
8. Inferring biochemical reaction pathways: the case of the gemcitabine pharmacokinetics.
Lecca P; Morpurgo D; Fantaccini G; Casagrande A; Priami C
BMC Syst Biol; 2012 May; 6():51. PubMed ID: 22640931
[TBL] [Abstract][Full Text] [Related]
9. Gemcitabine: metabolism, mechanisms of action, and self-potentiation.
Plunkett W; Huang P; Xu YZ; Heinemann V; Grunewald R; Gandhi V
Semin Oncol; 1995 Aug; 22(4 Suppl 11):3-10. PubMed ID: 7481842
[TBL] [Abstract][Full Text] [Related]
10. Population Pharmacokinetics of Gemcitabine and dFdU in Pancreatic Cancer Patients Using an Optimal Design, Sparse Sampling Approach.
Serdjebi C; Gattacceca F; Seitz JF; Fein F; Gagnière J; François E; Abakar-Mahamat A; Deplanque G; Rachid M; Lacarelle B; Ciccolini J; Dahan L
Ther Drug Monit; 2017 Jun; 39(3):290-296. PubMed ID: 28346313
[TBL] [Abstract][Full Text] [Related]
11. Ribonucleotide reductase is an effective target to overcome gemcitabine resistance in gemcitabine-resistant pancreatic cancer cells with dual resistant factors.
Minami K; Shinsato Y; Yamamoto M; Takahashi H; Zhang S; Nishizawa Y; Tabata S; Ikeda R; Kawahara K; Tsujikawa K; Chijiiwa K; Yamada K; Akiyama S; Pérez-Torras S; Pastor-Anglada M; Furukawa T; Yasuo T
J Pharmacol Sci; 2015 Mar; 127(3):319-25. PubMed ID: 25837929
[TBL] [Abstract][Full Text] [Related]
12. Cytidine deaminase polymorphism predicts toxicity of gemcitabine-based chemotherapy.
Ding X; Chen W; Fan H; Zhu B
Gene; 2015 Mar; 559(1):31-7. PubMed ID: 25582275
[TBL] [Abstract][Full Text] [Related]
13. Phase I dose-escalation study and population pharmacokinetic analysis of fixed dose rate gemcitabine plus carboplatin as second-line therapy in patients with ovarian cancer.
Leijen S; Veltkamp SA; Huitema AD; van Werkhoven E; Beijnen JH; Schellens JH
Gynecol Oncol; 2013 Sep; 130(3):511-7. PubMed ID: 23665458
[TBL] [Abstract][Full Text] [Related]
14. Intracellular pharmacokinetics of gemcitabine, its deaminated metabolite 2',2'-difluorodeoxyuridine and their nucleotides.
Derissen EJB; Huitema ADR; Rosing H; Schellens JHM; Beijnen JH
Br J Clin Pharmacol; 2018 Jun; 84(6):1279-1289. PubMed ID: 29451684
[TBL] [Abstract][Full Text] [Related]
15. Attempts to remodel the pathways of gemcitabine metabolism: Recent approaches to overcoming tumours with acquired chemoresistance.
Saiki Y; Hirota S; Horii A
Cancer Drug Resist; 2020; 3(4):819-831. PubMed ID: 35582220
[TBL] [Abstract][Full Text] [Related]
16. Is age just a number? A population pharmacokinetic study of gemcitabine.
Boosman RJ; Crombag MBS; van Erp NP; Beijnen JH; Steeghs N; Huitema ADR
Cancer Chemother Pharmacol; 2022 May; 89(5):697-705. PubMed ID: 35426526
[TBL] [Abstract][Full Text] [Related]
17. Predicting Chemotherapy-Induced Neutropenia and Granulocyte Colony-Stimulating Factor Response Using Model-Based In Vitro to Clinical Translation.
Chen W; Boras B; Sung T; Hu W; Spilker ME; D'Argenio DZ
AAPS J; 2020 Nov; 22(6):143. PubMed ID: 33156437
[TBL] [Abstract][Full Text] [Related]
18. The Emerging Role of Cytidine Deaminase in Human Diseases: A New Opportunity for Therapy?
Frances A; Cordelier P
Mol Ther; 2020 Feb; 28(2):357-366. PubMed ID: 31870623
[TBL] [Abstract][Full Text] [Related]
19. Prolonged low-dose infusion for gemcitabine: a systematic review.
Zhao D; Chen J; Chu M; Wang J
Onco Targets Ther; 2019; 12():4859-4868. PubMed ID: 31417283
[TBL] [Abstract][Full Text] [Related]
20. A novel liver-specific fluorescent anti-cancer drug delivery system using indocyanine green.
Inagaki Y; Kokudo T; Kamiya M; Uno SN; Sato M; Kaneko J; Kokudo N; Urano Y; Hasegawa K
Sci Rep; 2019 Feb; 9(1):3044. PubMed ID: 30816163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
